{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:46:57Z","timestamp":1769701617589,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011500","name":"Abigail Wexner Research Institute at Nationwide Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007520","name":"Nationwide Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jim.2025.114004","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:28:16Z","timestamp":1763083696000},"page":"114004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cell-based potency assay for anti-CD3-anti-CD19 diabody"],"prefix":"10.1016","volume":"545","author":[{"given":"Tania L.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Paniagua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonny","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2025.114004_bb0005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jim.2025.114004_bb0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jim.2025.114004_bb0020","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1126\/sciadv.abm1890","article-title":"Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics","volume":"8","author":"Cripe","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jim.2025.114004_bb0025","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jim.2025.114004_bb0030","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/1060028020988411","article-title":"A systematic review of blinatumomab in the treatment of acute lymphoblastic Leukemia: engaging an old problem with new solutions","volume":"55","author":"Halford","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jim.2025.114004_bb0035","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","article-title":"\u201cdiabodies\u201d: small bivalent and bispecific antibody fragments","volume":"90","author":"Holliger","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jim.2025.114004_bb0040","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jim.2025.114004_bb0010","article-title":"Development of a pharmacokinetic (PK) mouse serum GLP ELISA for an anti\u2013CD19\u2013AntiCD3 diabody","author":"Johnson","year":"2025","journal-title":"bioRxiv 03.19.644217"},{"key":"10.1016\/j.jim.2025.114004_bb0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2025.114004_bb0050","article-title":"Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jim.2025.114004_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6403","article-title":"PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia","author":"Li","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jim.2025.114004_bb0060","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cel killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jim.2025.114004_bb0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1078155215618770","article-title":"A review of blinatumomab, a novel immunotherapy","volume":"22","author":"Newman","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jim.2025.114004_bb0075","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood-2018-99-114503","article-title":"Patient\u2019s T cell functionality determines blinatumomab-mediated killing of B-ALL Leukemia cells","volume":"132","author":"Yin","year":"2018","journal-title":"Blood"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:01:44Z","timestamp":1769662904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175925002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":14,"alternative-id":["S0022175925002042"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2025.114004","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-based potency assay for anti-CD3-anti-CD19 diabody","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2025.114004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114004"}}